News
AstraZeneca Readies for Tagrisso Competition in First-Line Advanced Lung Cancer as Q2 Revenues Surge
The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.
In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...
MyChesCo on MSN1d
AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer
AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, ...
New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback